Summary
The product OXAN, manufactured by Driada Medical, was analyzed to verify its composition and potency. The sample, identified by batch number 654752, was tested by Janoshik Analytical, a laboratory with expertise in pharmaceutical quality control. The analysis confirmed the presence of oxandrolone, with a measured concentration of 10.74 mg per pill. This result reflects an accuracy of 107.4% compared to the labeled specification of 10 mg per pill, with a variance of 7.4% above the label claim.
Testing was commissioned and funded by the manufacturer, Driada Medical, and the sample was retested twice for accuracy. The analysis was completed on 28 February 2022. While the results closely align with the labeled claims, it is important to evaluate these findings critically, given the manufacturer’s involvement. This report is intended for educational and harm reduction purposes, providing transparency and guidance to consumers.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: OXAN
- Active Ingredient: Oxandrolone
- Batch Number: 654752
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #18691
- Testing Ordered: 21 February 2022
- Sample Received: 22 February 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 10 mg per pill (as stated on the label)
- Measured Concentration: 10.74 mg per pill
- Accuracy: 107.4% (7.4% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/18691_2QY94NH9XFY4
- Originally Published: https://thinksteroids.com/community/posts/2920247/
Evaluation of Manufacturer-Funded Testing
Since the testing was both submitted and funded by Driada Medical, the findings should be interpreted with caution. Manufacturer-funded testing can introduce potential biases, such as selective sampling. However, Janoshik Analytical’s reputation for reliability and transparency adds credibility to the results. Additionally, the retesting of the sample strengthens the validity of these findings.
Independent verification by a third-party laboratory would provide additional assurance of product consistency and quality.
Conclusion
The analysis of OXAN by Driada Medical demonstrates a concentration of oxandrolone slightly exceeding the labeled specification. The results validate the product’s potency and align with its label claims. This report emphasizes the importance of transparent testing in harm reduction, helping users make informed decisions about anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
